Thelansis

Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency Market Outlook Thelansis’s “Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales a...

  Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency Market Outlook Thelansis’s “Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency Overview Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency is a rare autosomal recessive disorder known as Aromatic L-amino acid decarboxylase deficiency, attributed to mutations in the DDC gene. This disorder arises from a deficiency in the enzyme aromatic L-amino acid decarboxylase (AAD...

  Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency is a rare autosomal recessive disorder known as Aromatic L-amino acid decarboxylase deficiency is attributed to mutations in the DDC gene. This disorder arises from a deficiency in the enzyme aromatic L-amino acid decarboxylase (AADC), which generally converts L-dopa and 5-hydroxytryptophan into dopamine and serotonin, respectively. The typical presentation of AADC deficiency in infants includes muscular hypotonia, oculogyric crises, and developmental delay. Additional features may include disturbances in thermoregulation, autonomic dysfunction, sleep disorders, dystonia, nasal congestion, feeding problems, and intellectual disability. The onset of initial symptoms can occur from the neonatal period up to 12 months of age, with a mean onset of around 2-3 months. While most reported cases exhibit a severe phenotype characterized by profound motor developmental impairment, some individuals present with a milder to moderate phe...